Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ORMP

ORMP - Oramed Pharmaceuticals Inc Stock Price, Fair Value and News

$3.47-0.01 (-0.29%)
Market Closed

48/100

ORMP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

48/100

ORMP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.14

Target 3M

$3.33

Target 6M

$3.26

ORMP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ORMP Price Action

Last 7 days

0.9%

Last 30 days

19.2%

Last 90 days

44.6%

Trailing 12 Months

54.2%

ORMP RSI Chart

ORMP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ORMP Valuation

Market Cap

138.1M

Price/Earnings (Trailing)

3.15

Price/Sales (Trailing)

71.29

EV/EBITDA

0.74

Price/Free Cashflow

-13.02

ORMP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.14

Target 3M

$3.33

Target 6M

$3.26

ORMP Fundamentals

ORMP Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ORMP Earnings

Earnings (TTM)

43.8M

Earnings Growth (Yr)

346.67%

Earnings Growth (Qtr)

264.2%

ORMP Profitability

Operating Margin

95.90%

EBT Margin

4160.00%

Return on Equity

21.55%

Return on Assets

19.87%

Free Cashflow Yield

-7.68%

ORMP Investor Care

Buy Backs (1Y)

1.26%

Diluted EPS (TTM)

0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
20231.9M2.2M1.5M1.3M
20222.8M2.5M2.5M1.7M
20212.9M2.9M2.7M2.8M
20202.7M2.7M2.7M2.7M
20192.6M2.6M2.7M2.7M
20182.5M2.5M2.4M2.5M
20171.5M2.0M2.5M2.5M
201600641.0K1.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Oramed Pharmaceuticals Inc

ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
0
 CEO
 WEBSITEoramed.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Oramed Pharmaceuticals Inc Frequently Asked Questions

ORMP is the stock ticker symbol of Oramed Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Oramed Pharmaceuticals Inc is 138.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ORMP's fair value in chart for subscribers.

The fair value guage provides a quick view whether ORMP is over valued or under valued. Whether Oramed Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Oramed Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORMP.

As of Wed Jan 28 2026, ORMP's PE ratio (Price to Earnings) is 3.15 and Price to Sales (PS) ratio is 71.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORMP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Oramed Pharmaceuticals Inc has provided -0.059 (multiply by 100 for percentage) rate of return.